None listed
Conditions
Brief summary
The prevalence of cancer diagnosis is high and attributable to 30% of all deaths in Australia. There is a need for better treatment combined with reliable assessments of treatment effectiveness. This pilot intervention study aims to assess the treatment effect and safety of Light-bed-PDT for patients with cancer using Circulating Tumour Cell (CTC) analyses. Who is it for? You may be eligible for this study, if you have been diagnosed with cancer. Study details Cancer patients will undergo 2 sessions of Light-bed Photodynamic Therapy (PDT) on 2 consecutive days. 1. Photodynamic Therapy, which involves participants being given a chlorophyll-derived liquid food product which will help absorb light 15-20 hours before 2. LED Light-Bed whole body therapy, which involves lying in a red-light-bed for 30 min. These treatments will be provided to participants 2 times on two consecutive days. A blood test measuring the number of Circulating Tumour Cells (CTC) before and 3 weeks after treatment will assess treatment effectiveness. Fluorescence photography of the ear lobe will also be performed before and after treatment. Tolerability and safety will be assessed after each treatment session. This study will provide insight into the safety and efficacy of Light-bed Photodynamic Therapy (PDT) in cancer patients.
Interventions
Cancer patients will undergo 2 sessions of Light-bed Photodynamic Therapy (PDT) on 2 consecutive days. Each PDT session consists of 2 steps. Step 1: oral administration of 5ml photosensitizer liquid containing 5mg of a chlorophyll-derivate extracted from algae. Step 2: followed by 30min of LED-Light-bed therapy 15-20 hours after dosing.
LED Light-bed therapy will be applied to the whole body using red light (630-700 nm).
SMS reminders will be sent to participants to assist with adherence to pro
Cancer patients will undergo 2 sessions of Light-bed Photodynamic Therapy (PDT) on 2 consecutive days. Each PDT session consists of 2 steps. Step 1: oral administration of 5ml photosensitizer liquid containing 5mg of a chlorophyll-derivate extracted from algae. Step 2: followed by 30min of LED-Light-bed therapy 15-20 hours after dosing. LED Light-bed therapy will be applied to the whole body using red light (630-700 nm). SMS reminders will be sent to participants to assist with adherence to protocol. Update to protocol after n=50 participants (half of target sample size): Participants are encouraged to consider Hyperbaric Oxygen Therapy (HBOT) immediately before Light-bed Therapy to enhance the therapeutic effect. While HBOT therapy is not part of this clinical trial, it will be noted whether participants have had a HBOT session before the Light-bed session. HBOT is provided as a clinical service, and all guidelines and eligibility criteria are to be adhered to.
Sponsors
National Institute of Integrative Medicine
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
adults diagnosed with cancer
Exclusion criteria
planned other treatment including surgery within 1 week Porphyria Claustrophobia, anxiety Not able to provide consent
Outcome results
None listed